In Raji lymphoma cells, 48-hour bafetinib pretreatment reduced surface CD20 antibody-binding signal and impaired subsequent rituximab- and ofatumumab-mediated complement-dependent cytotoxicity. This cell-based finding highlights a potential antagonistic interaction with anti-CD20 treatment. [1]
Bafetinib (5 μM, 30 minutes) attenuated B-cell receptor-triggered calcium mobilization and strongly reduced, but did not completely abolish, chemokine-triggered responses in patient-derived CLL cells. Responses varied among samples. [2]
In A375-derived SB01-VR melanoma cells, bafetinib plus trametinib reduced long-term viability signal and colony growth, with reduced ERK1/2 phosphorylation. At the tested 0.1–0.3 μM concentrations, bafetinib alone did not reduce the displayed 14-day viability signal below the DMSO reference. [3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Bafetinib pretreatment reduces CD20 signal and impairs antibody-mediated CDC
Cell-based study · Raji human B-cell lymphoma cells [1]
One integrated pretreatment experiment links lower surface CD20 signal with reduced complement-dependent cytotoxicity (CDC) after rituximab or ofatumumab. The bafetinib panels are Fig. 2A–C; NK-cell and animal findings in this paper involve other inhibitors and are not attributed to bafetinib.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500, 1000 or 5000 nM bafetinib; zero-inhibitor reference.
- Exposure duration
- 48 h pretreatment; after washing, 1 h CDC assay.
- Method
- Surface staining/flow cytometry and antibody-plus-serum CDC assay.
- Vehicle
- DMSO stock solvent (Reagents); solvent matching of zero-inhibitor reference is not explicitly stated in Fig. 2.
- Co-treatment
- Sequential bafetinib pretreatment followed by rituximab or ofatumumab (1–100 μg/ml) with 10% human AB serum; not a simultaneous in vivo combination.
- Reported limits
- Within-experiment replicate number is not given in the selected caption. Fig. S2 toxicity controls were not retrieved; no independent non-toxic-concentration claim is made.
Methods and source locations
Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib
Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.
Fig. 2A–C and caption; Results: Inhibitors of SRC family kinases downregulate CD20 levels and impair antitumor activity of anti-CD20 mAbs in Raji cells; Methods: Reagents, Cytotoxicity assay, Staining of surface antigens
Surface CD20 antibody-binding signal in viable Raji cells: Flow cytometry with FITC anti-CD20 clone L27; PI-negative cells; Fig. 2A. — Fig. 2A, middle panel; caption; Staining of surface antigens
Rituximab- and ofatumumab-mediated complement-dependent cytotoxicity after inhibitor washout: After 48 h pretreatment, cells were washed and exposed for 1 h to 1–100 μg/ml antibody plus 10% human AB serum; viability measured with PI. — Fig. 2B–C, middle panels and caption
Bafetinib suppresses BCR- and chemokine-triggered calcium responses
Cell-based study · Ex vivo peripheral-blood CLL samples; included samples had >85% CD19-positive cells. Fig. 6 caption n = 11; Results narrative says ten patients. [2]
At 5 μM, bafetinib reduced BCR-triggered calcium release and strongly diminished responses to CXCL13, CCL21 and CCL19 relative to equal-volume DMSO. Residual and exceptional responses remained. This functional endpoint does not establish an isolated Lyn biochemical IC50 or clinical efficacy.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM bafetinib.
- Exposure duration
- 30 min inhibitor incubation; calcium signal recorded for 2 min after stimulus.
- Method
- Fluo-3-AM calcium mobilization by flow cytometry; peak fluorescence minus pre-stimulation baseline.
- Vehicle
- Equal volume DMSO control.
- Co-treatment
- Bafetinib tested separately from ibrutinib and R406; receptor agonists are assay stimuli.
- Reported limits
- Patient number differs between narrative (ten) and Fig. 6 caption (n = 11); unresolved. Exact per-sample values and vehicle percentage not extracted.
Methods and source locations
Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib
Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.
Fig. 6 and caption; Results: Inhibition of Syk, Lyn, and Btk strongly reduces chemokine-induced calcium responses; Methods: Patient samples and cell isolation, Reagents, Intracellular calcium measurement
Stimulus-evoked intracellular calcium mobilization: Fluo-3-AM flow cytometry; after 30 min inhibitor exposure, record baseline and stimulus response; compare equal-volume DMSO. IgM/IgD F(ab′)2 10 μg/ml, CXCL13 500 ng/ml, CCL21/CCL19 200 ng/ml. — Fig. 6 and caption; final Results subsection; Intracellular calcium measurement
Bafetinib plus trametinib in melanoma cells with acquired vemurafenib resistance
Cell-based study · A375-derived SB01-VR melanoma reporter cells [3]
Combination treatment lowered the 14-day viability signal and colony growth more than either drug alone, with reduced ERK1/2 phosphorylation in the 24 h immunoblot. Bafetinib alone at 0.1 or 0.3 μM did not lower the displayed long-term viability signal below the DMSO reference. The experiments do not establish direct ERK binding or formal pharmacological synergy.
Literature-Reported Treatment Conditions
- Treatment concentration
- Fig. 6a: bafetinib 0.1 or 0.3 μM; trametinib 0.0003 or 0.001 μM. Fig. 6c uses 0.3 μM bafetinib with the two trametinib concentrations.
- Exposure duration
- 14 days for viability/colonies; 24 h for immunoblot. Medium and drugs replaced after 7 days for long-term assays.
- Method
- Long-term CellTiter-Glo, colony formation and pERK1/2 immunoblot.
- Vehicle
- 0.5% DMSO for colony assays per Methods; Fig. 6a uses DMSO control without an explicit percentage in its caption.
- Co-treatment
- Bafetinib plus trametinib, with both single agents and DMSO comparators.
- Reported limits
- Replicate number and error-bar definition are not specified in the Fig. 6 caption. No direct ERK enzyme inhibition or formal synergy analysis adopted.
Methods and source locations
Compound reported in the paper: Bafetinib (INNO-406; NS-187); Compound label in the paper: bafetinib
Evidence concerns the material used in this paper. It does not validate the identity, purity, potency or performance of a current commercial lot.
Fig. 6a–c and caption; Results: Identification of a potential novel drug combination to address BRAF resistant melanoma; Methods: Colony and Cell Proliferation Assays, Western Blot, compound list in Gaussia Luciferase Assay
14-day viable-cell-associated luminescence: CellTiter-Glo viability assay per caption; labels transcribed from viewed figure, not calculated from bar heights. Displayed error-bar definition/replicate n not specified in Fig. 6 caption. — Fig. 6a and caption; Colony and Cell Proliferation Assays
ERK1/2 phosphorylation and colony formation under combination treatment: 24 h immunoblot includes total ERK1/2 and actin controls (Fig. 6b); 14-day colony staining with DMSO and single-agent controls (Fig. 6c). — Fig. 6b–c and caption; Western Blot; Colony and Cell Proliferation Assays